Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [24]
- Comments [0]
- Validations
- Western blot [1]
- Immunoprecipitation [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11337-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11337-1-AP, RRID:AB_2190784
- Product name
- ENT1 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated ENT1 antibody (Cat. #11337-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, IP, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin.
The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells.
Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma.
Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy.
Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
Correlation of 4'-[methyl-11C]-thiothymidine uptake with human equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in patients with newly diagnosed gliomas.
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.
DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study.
Deficient Insulin-mediated Upregulation of the Equilibrative Nucleoside Transporter 2 Contributes to Chronically Increased Adenosine in Diabetic Glomerulopathy.
Reduced Adenosine Uptake and Its Contribution to Signaling that Mediates Profibrotic Activation in Renal Tubular Epithelial Cells: Implication in Diabetic Nephropathy.
p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines.
The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Expression of equilibrative nucleoside transporter 1 in rat circumvallate papillae.
Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
Peroxynitrite treatment reduces adenosine uptake via the equilibrative nucleoside transporter in rat astrocytes.
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Contribution of P2X7 receptors to adenosine uptake by cultured mouse astrocytes.
Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, Nezu Y, Ke S, Qiu C, Ohuchida K, Oda Y, Lee TH, Wegiel B, Clohessy JG, London N, Santagata S, Wulf GM, Hidalgo M, Muthuswamy SK, Nakamura M, Gray NS, Zhou XZ, Lu KP
Cell 2021 Sep 2;184(18):4753-4771.e27
Cell 2021 Sep 2;184(18):4753-4771.e27
RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin.
Chun JW, Lee B, Park WS, Han N, Hong EK, Park EY, Han SS, Park SJ, Kim TH, Lee WJ, Woo SM
Journal of clinical medicine 2021 Oct 11;10(20)
Journal of clinical medicine 2021 Oct 11;10(20)
The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
Chen L, Wang Z, Xu Q, Liu Y, Chen L, Guo S, Wang H, Zeng K, Liu J, Zeng S, Yu L
Theranostics 2020;10(8):3562-3578
Theranostics 2020;10(8):3562-3578
Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells.
Ye Z, Hu Q, Zhuo Q, Zhu Y, Fan G, Liu M, Sun Q, Zhang Z, Liu W, Xu W, Ji S, Yu X, Xu X, Qin Y
American journal of cancer research 2020;10(4):1182-1193
American journal of cancer research 2020;10(4):1182-1193
Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
Dai S, Peng Y, Zhu Y, Xu D, Zhu F, Xu W, Chen Q, Zhu X, Liu T, Hou C, Wu J, Miao Y
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 Jan;121:109521
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 Jan;121:109521
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M, Zhang Y, Yang J, Cui X, Zhou Z, Zhan H, Ding K, Tian X, Yang Z, Fung KA, Edil BH, Postier RG, Bronze MS, Fernandez-Zapico ME, Stemmler MP, Brabletz T, Li YP, Houchen CW, Li M
Gastroenterology 2020 Feb;158(3):679-692.e1
Gastroenterology 2020 Feb;158(3):679-692.e1
Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma.
Sun Q, Xu W, Ji S, Qin Y, Liu W, Hu Q, Zhang Z, Liu M, Yu X, Xu X
Cancer cell international 2019;19:49
Cancer cell international 2019;19:49
Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy.
Ma Z, Lu S, Sun D, Bai M, Jiang T, Lin N, Zhou H, Zeng S, Jiang H
British journal of pharmacology 2019 Sep;176(17):3236-3249
British journal of pharmacology 2019 Sep;176(17):3236-3249
Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
Meng Q, Shi S, Liang C, Liang D, Hua J, Zhang B, Xu J, Yu X
Oncogene 2018 Nov;37(44):5843-5857
Oncogene 2018 Nov;37(44):5843-5857
Correlation of 4'-[methyl-11C]-thiothymidine uptake with human equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in patients with newly diagnosed gliomas.
Takami Y, Yamamoto Y, Ueno M, Chiba Y, Norikane T, Hatakeyama T, Miyake K, Toyohara J, Nishiyama Y
Annals of nuclear medicine 2018 Nov;32(9):634-641
Annals of nuclear medicine 2018 Nov;32(9):634-641
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
Freiburghaus C, Emruli VK, Johansson A, Eskelund CW, Grønbæk K, Olsson R, Ek F, Jerkeman M, Ek S
BMC cancer 2018 Apr 25;18(1):466
BMC cancer 2018 Apr 25;18(1):466
FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.
Hu Q, Qin Y, Zhang B, Liang C, Ji S, Shi S, Xu W, Xiang J, Liang D, Ni Q, Yu X, Xu J
Oncology reports 2017 Oct;38(4):2069-2077
Oncology reports 2017 Oct;38(4):2069-2077
DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study.
Woo SM, Yoon KA, Hong EK, Park WS, Han SS, Park SJ, Joo J, Park EY, Lee JH, Kim YH, Kim TH, Lee WJ
Oncotarget 2017 Oct 6;8(46):81394-81404
Oncotarget 2017 Oct 6;8(46):81394-81404
Deficient Insulin-mediated Upregulation of the Equilibrative Nucleoside Transporter 2 Contributes to Chronically Increased Adenosine in Diabetic Glomerulopathy.
Alarcón S, Garrido W, Vega G, Cappelli C, Suárez R, Oyarzún C, Quezada C, San Martín R
Scientific reports 2017 Aug 25;7(1):9439
Scientific reports 2017 Aug 25;7(1):9439
Reduced Adenosine Uptake and Its Contribution to Signaling that Mediates Profibrotic Activation in Renal Tubular Epithelial Cells: Implication in Diabetic Nephropathy.
Kretschmar C, Oyarzún C, Villablanca C, Jaramillo C, Alarcón S, Perez G, Díaz-Encarnación MM, Pastor-Anglada M, Garrido W, Quezada C, San Martín R
PloS one 2016;11(1):e0147430
PloS one 2016;11(1):e0147430
p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines.
Moon SU, Kim JW, Sung JH, Kang MH, Kim SH, Chang H, Lee JO, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS
Cancer research and treatment 2015 Jul;47(3):501-8
Cancer research and treatment 2015 Jul;47(3):501-8
The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
Hummel-Eisenbeiss J, Hascher A, Hals PA, Sandvold ML, Müller-Tidow C, Lyko F, Rius M
Molecular pharmacology 2013 Sep;84(3):438-50
Molecular pharmacology 2013 Sep;84(3):438-50
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A, Amano R, Yamada N, Kimura K, Yashiro M, Nakata B, Hirakawa K
World journal of surgical oncology 2013 May 27;11:117
World journal of surgical oncology 2013 May 27;11:117
Expression of equilibrative nucleoside transporter 1 in rat circumvallate papillae.
Nishida K, Kitada T, Kato J, Dohi Y, Nagasawa K
Neuroscience letters 2013 Jan 15;533:104-8
Neuroscience letters 2013 Jan 15;533:104-8
Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
Kawada N, Uehara H, Katayama K, Nakamura S, Takahashi H, Ohigashi H, Ishikawa O, Nagata S, Tomita Y
Journal of hepato-biliary-pancreatic sciences 2012 Nov;19(6):717-22
Journal of hepato-biliary-pancreatic sciences 2012 Nov;19(6):717-22
The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
Matsumura N, Nakamura Y, Kohjimoto Y, Inagaki T, Nanpo Y, Yasuoka H, Ohashi Y, Hara I
BJU international 2011 Jul;108(2 Pt 2):E110-6
BJU international 2011 Jul;108(2 Pt 2):E110-6
Peroxynitrite treatment reduces adenosine uptake via the equilibrative nucleoside transporter in rat astrocytes.
Tanaka A, Nishida K, Okuda H, Nishiura T, Higashi Y, Fujimoto S, Nagasawa K
Neuroscience letters 2011 Jul 1;498(1):52-6
Neuroscience letters 2011 Jul 1;498(1):52-6
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Komori S, Osada S, Mori R, Matsui S, Sanada Y, Tomita H, Tokuyama Y, Takahashi T, Yamaguchi K, Yoshida K
Pancreas 2010 Nov;39(8):1284-92
Pancreas 2010 Nov;39(8):1284-92
Contribution of P2X7 receptors to adenosine uptake by cultured mouse astrocytes.
Okuda H, Higashi Y, Nishida K, Fujimoto S, Nagasawa K
Glia 2010 Nov 1;58(14):1757-65
Glia 2010 Nov 1;58(14):1757-65
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- mouse brain tissue were subjected to SDS PAGE followed by western blot with 11337-1-AP(ENT1 antibody) at dilution of 1:500
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- IP Result of anti-ENT1 (IP:11337-1-AP, 3ug; Detection:11337-1-AP 1:400) with mouse brain tissue lysate 8000ug.
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ENT1 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human ENT1. This antibody recognizes human,mouse,rat antigen. The ENT1 antibody has been validated for the following applications: ELISA, WB, IHC, IP analysis.
